The exploratory analysis for the efficacy and safety of Rikkunshito for upper gastrointestinal symptoms in the patients with functional dyspepsia

The exploratory analysis for the efficacy and safety of Rikkunshito for upper gastrointestinal symptoms in the patients with functional dyspepsia - The analysis for the efficacy and safety of Rikkunshito for the patients with functional dyspepsia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001922

Enrollment

Registered

2009-05-01

Start date

2008-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

Rikkunshito 7.5g per day before meal 4 weeks Domperidone 30mg per day before meal 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients diagnosed as functional dyspepsia by the Rome III criteria

Exclusion criteria

Exclusion criteria: The patients (1)after removal of their stomach (2)with heart failure or severe inflammation (3)with disorder in liver, gallbladder, or pancreas (4)with pregnancy, or breast-feeding now (5)with astrointestinal bleeding, mechanical ileus, perforation in gastrointestine (6)taking prohibited drug during trial (7) impossible to take a drug per oral (8)taking herbal medicine during trial (9)who are unsuitable judged by the responsible person

Design outcomes

Primary

Measure	Time frame
The upper gastrointestinal symptoms at 2 and 4 weeks after drug administartion	—

Secondary

Measure	Time frame
The change of the level in the hormone related to appetite at 2 and 4 weeks after drug administartion	—

Countries

Japan

Contacts

Public ContactMAKOTO ARAI

Graduate School of Medicine, Medicine and Clinical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026